89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

89bio (NASDAQ:ETNB) CEO Rohan Palekar presented at the Cantor Global Healthcare Conference, highlighting progress on their FGF21 analog, pegozafermin, which is currently in three Phase III studies. The company expects to report results from its pivotal SHTG program early next year, marking the first major readout. Additionally, two MASH programs, including one targeting the high-unmet-need compensated cirrhosis population, are actively enrolling patients, with pegozafermin viewed as potentially transformational in MASH.

Analysis

89bio, Inc. (ETNB) management has presented a confident forward outlook for its lead asset, pegozafermin, an FGF21 analog progressing through three distinct Phase III programs. The most significant near-term catalyst is the pivotal study in SHTG, which has completed enrollment with a data readout expected in early 2026. This will serve as the first major validation point from its late-stage pipeline. Concurrently, the company is actively enrolling patients in two MASH studies, one in pre-cirrhotic MASH and another targeting compensated cirrhosis. The CEO specifically framed the cirrhosis indication as a 'transformational' opportunity, citing the 'highest unmet need' in this patient population. The optimistic tone of the update, reflected in a strongly positive sentiment score of 0.75, underscores high internal conviction in pegozafermin's potential across multiple large-market indications.

Key Decisions for Investors

• Investors should monitor 89bio for the pivotal Phase III data from its SHTG program, expected in early 2026, as this represents the next major valuation catalyst for the stock.
• The long-term investment thesis is heavily weighted towards success in the two ongoing MASH trials, particularly in the compensated cirrhosis population, which management has identified as a key value driver.
• Given the company is a clinical-stage biotech, exposure to ETNB carries significant binary risk dependent on clinical trial outcomes, and any negative data from the upcoming SHTG readout would materially impact the company's valuation.